GTS5:Table of Contents: Difference between revisions

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search
No edit summary
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 50: Line 50:
   - [[GTS5:Activated Phosphatidylinositol-3-OH kinase δ Syndrome - APDS (PIK3CD)]]
   - [[GTS5:Activated Phosphatidylinositol-3-OH kinase δ Syndrome - APDS (PIK3CD)]]


'''Transcription factors and regulators'''
'''Transcription factors and regulators'''
 
   - [[GTS5:Multiple endocrine neoplasia type 5, MAX related tumours (MAX)]]
   - [[GTS5:Multiple endocrine neoplasia type 5, MAX related tumours (MAX)]]
   - [[GTS5:MAFA-related familial insulinomatosis (MAFA)]]
   - [[GTS5:MAFA-related familial insulinomatosis (MAFA)]]
Line 60: Line 59:
==Oxidative stress response and metabolism ([[GTS5:Oxidative stress response and metabolism|Overview Page Link]])==
==Oxidative stress response and metabolism ([[GTS5:Oxidative stress response and metabolism|Overview Page Link]])==


'''Angiogenesis'''
'''Angiogenesis'''
   - [[GTS5:Von Hippel-Lindau syndrome (VHL)]]
   - [[GTS5:Von Hippel-Lindau syndrome (VHL)]]


Line 67: Line 66:
   - [[GTS5:Hereditary leiomyomatosis and renal cell carcinoma syndrome (FH)]]
   - [[GTS5:Hereditary leiomyomatosis and renal cell carcinoma syndrome (FH)]]


  '''Toxic metabolite-mediated disorders'''
'''Toxic metabolite-mediated disorders'''
   - [[GTS5:Hereditary tyrosinaemia type 1 (FAH)]]
   - [[GTS5:Hereditary tyrosinaemia type 1 (FAH)]]


Line 92: Line 91:


  '''Homologous recombination'''
  '''Homologous recombination'''
   - [[GTS5:BRCA-related cancer predisposition syndrome (BRCA1, BRCA2)]]
   - [[GTS5:BRCA-related cancer predisposition syndrome (BRCA1, BRCA2)]]
   - [[GTS5:PALB2-related cancer predisposition syndrome (PALB2)]]
   - [[GTS5:PALB2-related cancer predisposition syndrome (PALB2)]]
Line 127: Line 125:


==Telomere maintenance ([[GTS5:Telomere maintenance|Overview Page Link]])==
==Telomere maintenance ([[GTS5:Telomere maintenance|Overview Page Link]])==
 
  '''Telomere biology disorders'''
  '''Telomere biology disorders'''
   - [[GTS5:Dyskeratosis congenita (DKC1, TERT, TERC, TINF2, Other IBMFS genes)]]
   - [[GTS5:Dyskeratosis congenita (DKC1, TERT, TERC, TINF2, Other IBMFS genes)]]

Latest revision as of 10:58, 5 June 2025

Growth factor receptors and related signalling pathways (Overview Page Link)

Growth factor receptors
  - GTS5:Hereditary papillary renal carcinoma (MET)
  - GTS5:Multiple endocrine neoplasia type 2 (RET)
  - GTS5:Juvenile polyposis syndrome (BMPR1A, SMAD4)
  - GTS5:Hereditary neuroblastoma (ALK, PHOX2B)
  - GTS5:Encephalocraniocutaneous lipomatosis (FGFR1)
G-coupled protein receptor pathway
  - GTS5:Glucagon cell hyperplasia and neoplasia (GCGR)
  - GTS5:McCune-Albright syndrome (GNAS)
  - GTS5:Sturge-Weber syndrome (GNAQ)
RAS-MAPK pathway
  - GTS5:Neurofibromatosis type 1 (NF1)
  - GTS5:NF2-related schwannomatosis (NF2)
  - GTS5:Costello syndrome (HRAS)
  - GTS5:Noonan syndrome (Various genes)
  - GTS5:Schimmelpenning-Feuerstein-Mims (HRAS, KRAS)
PKA signalling pathway
  - GTS5:Carney complex (PRKAR1A, PDE8B, PDE11A)
  - GTS5:PROS syndrome (PIK3CA)
WNT/TGFbeta pathway
  - GTS5:Familial adenomatous polyposis (APC)
  - GTS5:Gastric Adenocarcinoma and Proximal Polyposis of Stomach - GAPPS (APC promoter)
  - GTS5:AXIN2-associated polyposis (AXIN2)
  - GTS5:Serrated polyposis (RNF43)
  - GTS5:WT1 related tumour predisposition syndrome (WT1)
  - GTS5:WAGR syndrome (WT1)
  - GTS5:Multiple endocrine neoplasia type 1 (MEN1)
  - GTS5:Peutz-Jeghers syndrome (STK11)
  - GTS5:Hereditary gastric and breast cancer syndrome (CDH1, CTNNA1)
  - GTS5:Hereditary mixed polyposis syndrome (GREM1)
Hedgehog signalling pathway
  - GTS5:Naevoid basal cell carcinoma syndrome - Gorlin syndrome (PTCH1, SUFU, GPR161)
  - GTS5:SMO-related Curry-Jones syndrome (SMO)
  - GTS5:ELP1-related medulloblastoma predisposition syndrome(ELP1)
  - GTS5:Osteochondromatosis (EXT1, EXT2)
NF-kB signalling pathway
  - GTS5:Brooke-Spiegler syndrome (CYLD)
MTOR and PI3K pathway
  - GTS5:Tuberous sclerosis (TSC1, TSC1)
  - GTS5:PTEN hamartoma tumour syndrome (PTEN)
  - GTS5:Activated Phosphatidylinositol-3-OH kinase δ Syndrome - APDS (PIK3CD)
Transcription factors and regulators
  - GTS5:Multiple endocrine neoplasia type 5, MAX related tumours (MAX)
  - GTS5:MAFA-related familial insulinomatosis (MAFA)
  - GTS5:Birt-Hogg-Dube syndrome (FLCN)
  - GTS5:Familial chordoma (TBXT)
  - GTS5:Hyperparathyroidism jaw tumour syndrome (CDC73)

Oxidative stress response and metabolism (Overview Page Link)

Angiogenesis
  - GTS5:Von Hippel-Lindau syndrome (VHL)
Krebs cycle
  - GTS5:SDH-deficient tumour syndrome - Hereditary phaeochromocytoma-paraganglioma syndromes (SDHA, SDHB, SDHC, SDHD, SDHAF2)
  - GTS5:Hereditary leiomyomatosis and renal cell carcinoma syndrome (FH)
Toxic metabolite-mediated disorders
  - GTS5:Hereditary tyrosinaemia type 1 (FAH)

Cell cycle and apoptosis pathways (Overview Page Link)

P53 pathway
  - GTS5:Li-Fraumeni syndrome (TP53)
RB pathway
  - GTS5:Retinoblastoma syndrome (RB1)
  - GTS5:Multiple endocrine neoplasia type 4 (CDKN1B)
  - GTS5:CDKN2A-related tumour predisposition syndrome (CDKN2A)
  - GTS5:CDK4-related melanoma predisposition syndrome (CDK4)
FAS pathway
  - GTS5:Autoimmune lymphoproliferative syndrome (FAS)

DNA repair and genomic stability (Overview Page Link)

Mismatch repair
  - GTS5:Lynch Syndrome (MLH1, PMS2, MSH2, MSH6)
  - GTS5:Muir-Torre syndrome (MLH1, PMS2, MSH2, MSH6)
  - GTS5:Constitutional mismatch repair deficiency (CMMRD) syndrome (MLH1, PMS2, MSH2, MSH6)
Homologous recombination
  - GTS5:BRCA-related cancer predisposition syndrome (BRCA1, BRCA2)
  - GTS5:PALB2-related cancer predisposition syndrome (PALB2)
  - GTS5:RAD51-related cancer predisposition syndrome (RAD51C, RAD51D)
  - GTS5:Fanconi anaemia (FANC genes)
Base excision repair genes
  - GTS5:MUTYH-associated polyposis (MUTYH)
  - GTS5:NTHL1-related tumour syndrome (NTHL1)
  - GTS5:MBD4-associated neoplasia syndrome (MBD4)
Deficient nucleotide excision repair (NER) of DNA damage
  - GTS5:Xeroderma Pigmentosum
Non-homologous end joining (NHEJ)
  - GTS5:Ataxia-telangiectasia syndrome (ATM)
  - GTS5:CHEK2-related hereditary (breast) cancer predisposition syndrome (CHEK2)
  - GTS5:Nijmegen breakage syndrome (NBN)
DNA Polymerization
  - GTS5:Polymerase proofreading-associated polyposis (POLD1, POLE)
Helicases
  - GTS5:Bloom syndrome (BLM)
  - GTS5:Werner syndrome (WRN)
  - GTS5:Rothmund-Thomson syndrome (ANAPC1, RECQL4)
  - GTS5:DDX41-related haematologic tumour predisposition syndrome (DDX41)
Chromosomal non-dysjunction (aneuploidy) syndromes
  - GTS5:Mosaic variegated aneuploidy (BUB1B, CEP57, TRIP13, BUB1, BUB3)
  - GTS5:Klinefelter syndrome
  - GTS5:Turner syndrome
  - GTS5:Down syndrome

Telomere maintenance (Overview Page Link)

Telomere biology disorders
  - GTS5:Dyskeratosis congenita (DKC1, TERT, TERC, TINF2, Other IBMFS genes)
  - GTS5:POT1 and Shelterin-related tumour predisposition syndrome (POT1, ACD, TERF2IP, TERT promoter)

Epigenetic drivers and chromatin remodelling (Overview Page Link)

Imprinting disorders
  - GTS5:Beckwith-Wiedemann spectrum (IGF2; CDKN1C)
Histone and DNA methylation
  - GTS5:Enchondromatosis (IDH1, IDH2)
Chromatin remodelling pathway
  - GTS5:Rhabdoid tumour predisposition syndrome (SMARCB1, SMARCA4)
  - GTS5:Schwannomatosis (SMARCB1, LZTR1)
  - GTS5:Clear cell meningioma predisposition syndrome (SMARCE1)
  - GTS5:Weaver syndrome (EZH2)

RNA regulation (Overview Page Link)

MicroRNA
  - GTS5:DICER1-related tumour predisposition syndrome (DICER1)
  - GTS5:MicroRNA processor tumour predisposition syndromes (DROSHA, DGCR8)
RNA splicing
  - GTS5:Goldenhar syndrome (MYT1, SF3B2)

Protein regulation (Overview Page Link)

Ubiquitin pathway
  - GTS5:BAP1-related tumour predisposition syndrome (BAP1)